drugset / Trial / NCT06132932
A Study of WX390 in Patients With Advanced Solid Tumors With PIK3CA Mutations
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 in patients with advanced solid tumors. The main question it aims to answer is: • safety and preliminary efficacy in WX390 therapy. Participants will be treated with WX390 orally and follow the efficacy and safety evaluation according to the protocol.
Timeline
- Start
- 2021-06-03
- Primary completion
- 2023-01-03
- Completion
- 2023-01-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WX390 | Unknown | 1.1 mg | Oral |
Indications
No indication recorded.